tbuckley/cabot-search huggingface dataset:
Advances in the Decision to Image or Not to Image
Authors: Michael J. Callahan, Keith J. Strauss
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Anticancer prescription appropriateness: The APA score—A new method to assess anticancer prescriptions in the clinical setting.
Authors: V. Launay-Vacher, O. Aujoulat, M. Brandely, R. Chevrier, L. Dumas, B. Favier, A. Pelloquin, C. Rioufol, J. Rey
Journal: Journal of Clinical Oncology (2011)

261 Background: Innovation is crucial in cancer care and access to innovation cannot be—only—economically ruled. We need new drugs, more effective and/or better tolerated to improve the care of our patients. In this context, we need new tools to evaluate the appropriateness of anticancer drugs prescriptions. In fact, the better the appropriateness, the better is the patient care, and the overall balance, including economically. Methods: A group of 9 pharmacists from university hospitals, general hospitals, and cancer centres joined under the umbrella of the European Fellowship for Pharmacists (EFP) association. The aim was to set up a common process in evaluating the appropriateness of anticancer drugs prescriptions (ADP), focusing on innovative drugs, but not only. Results: The backbone of our work was to put back the patient at the centre and not to focus on the costs as themselves. We defined a composite criterium called “value of an ADP” which included the costs of course in addition to several factors such as the existence of alternatives for a particular patient, the level of evidence from literature data, the existence of other indications, and several other items. First, a decision tree was elaborated, which allows systematic and standardized screening of ADP leading to early identification of ADP which do not necessitate thorough evaluation: prescription within the terms of either a market authorisation or a Temporary Therapeutic Protocol, or a Temporary Utilization Authorization (ATU), and not on a clinical trial. For the other prescriptions, an evaluation grid coupled to a score was set up. This APA Score (Anticancer Prescription Appropriateness) will allow to decide whether or not a ADP, in a particular clinical context and patient, should be judged as appropriate or not. Conclusions: At the time of this abstract: the evaluation grid has been discussed, modified, and validated with the participation of two clinical oncologists, specialized in Breast Cancer; the APA scoring is currently under testing by a team of methodologists and bio-mathematicians; and the grid and the APA Score will be tested in “real-life” within the departments of the people involved in the group by the end of 2011.
Continued Benefit From Prolonged Treatment with Eculizumab in 130 Patients with PNH in the UK: Home Delivery of Eculizumab Is Safe, Convenient and Associated with Very High Levels of Patient Satisfaction
Authors: Louise M Arnold, Gemma L Brooksbank, Richard J Kelly, Anita Hill, Stephen John Richards, Rachel Senior, Tracy Downing, Claire McKinley, James Brown, Ibrahim Momoh, Modupe Elebute, Peter Hillmen
Journal: Blood (2011)
A meta-analysis of bevacizumab plus interferon alfa for previously untreated patients with metastatic clear-cell renal carcinoma (mRCC).
Authors: Z. Likun, Y. Ba
Journal: Journal of Clinical Oncology (2011)

366 Background: mRCC was highly resistant to conventional chemotherapy. Both CALGB study and AVOREN study failed to detect statistic differences in overall survival (OS). To evaluate the effectiveness and adverse-effect of bevacizumab plus IFN-α for untreated mRCC, we performed a meta-analysis. Methods: We searched RCTs that compared bevacizumab plus IFN- alpha with other treatments. For trials without heterogeneity, meta-analysis was carried out by using review manager (Revman 4.2) with fixed or random-effects models. Hazard ratio (HR), relative risk (RR), and 95 percent confidence intervals (CI) were calculated. The primary outcome was overall survival. The secondary outcomes were PFS and the adverse effects. Subgroup analyses were performed by MSKCC risk factors. Results: Two RCTs (CALGB study and AVOREN study) were identified as eligible for inclusion in our meta-analysis. Overall survival: Meta- analysis including 1,381 patients showed a trend in favor of bevacizumab plus IFN-alpha with an HR of 0.89 (95% CI, 0.80-1.00, p=0.05). Meta-analysis of OS which adjusted on stratification factors showed extent improvement in favor of bevacizumab plus IFN-alpha (HR=0.86, 95% CI, 0.76-0.97, p=0.02). Progress-free survival: Meta-analyses showed statistic differences in favor of bevacizumab plus IFN-alpha in both unstratified PFS (HR=0.68, 95% CI, 0.61-0.77, p&lt;0.00001) and stratified PFS (HR=0.67, 95% CI, 0.59-0.75, p&lt;0.00001). Subgroup analysis: There were no statistic differences between bevacizumab plus IFN-alpha and IFN-alpha in MSKCC favorable risk group (HR=0.91, 95% CI, 0.70-1.17, p=0.45) and MSKCC poor risk group (HR=0.79, 95% CI, 0.55-1.14, p=0.21). For MSKCC intermediate risk group, there was statistic difference in favor of bevacizumab plus IFN-alpha (HR=0.85, 95% CI, 0.73-0.99, p=0.04). Adverse effects: There were statistic differences in favor ofIFN-alpha in anorexia, fatigue proteinuria, and bleeding, while no statistic difference in gastrointestinal perforation. Conclusions: Bevacizumab plus IFN-alpha prolonged both OS and PFS as first line therapy for mRCC, especially for MSKCC intermediate risk group. The toxicity was acceptable and well tolerated. No significant financial relationships to disclose.
Early Stage Diffuse Large B Cell Lymphoma (DLBCL) in the CHOP-R Era: Does Involved Field Radiation Therapy (IFRT) Impact Outcome?.
Authors: Manzurul A. Sikder, Sughosh Dhakal, Jennifer Kelly, Steven H. Bernstein, Faith Young, Richard I. Fisher, Jonathan Friedberg, Louis Constine
Journal: Blood (2007)
Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation.
Authors: Marco Mielcarek, Lauri Burroughs, Wendy Leisenring, Paul Martin, Razvan Diaconezcu, Brenda Sandmaier, David Maloney, Thomas Chauncey, Michael Maris, Judith Shizuru, Karl Blume, Ute Hegenbart, Dietger Niederwieser, Stephen Forman, Benedetto Bruno, Ann Woolfrey, Rainer Storb
Journal: Blood (2004)
Early Lymphocyte Recovery Predicts Superior Disease Free Survival and Overall Survival after High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma Patients
Authors: Walter G Borelli, Cristina Otero, Ana Ines Landoni, Alicia Magariños, Mercedes Zamora, Elena De Lisa, Martín Ferrando, De Giuda Rosanna, Martínez Claudia, Ana Prado, Alberto Vazquez, Raul Gabus
Journal: Blood (2014)
CD4+ T cell effector commitment coupled to self-renewal by asymmetric cell divisions
Authors: Simone A. Nish, Kyra D. Zens, Radomir Kratchmarov, Wen-Hsuan W. Lin, William C. Adams, Yen-Hua Chen, Bonnie Yen, Nyanza J. Rothman, Avinash Bhandoola, Hai-Hui Xue, Donna L. Farber, Steven L. Reiner
Journal: The Journal of Experimental Medicine (2016)

Upon infection, an activated CD4+ T cell produces terminally differentiated effector cells and renews itself for continued defense. In this study, we show that differentiation and self-renewal arise as opposing outcomes of sibling CD4+ T cells. After influenza challenge, antigen-specific cells underwent several divisions in draining lymph nodes (LN; DLNs) while maintaining expression of TCF1. After four or five divisions, some cells silenced, whereas some cells maintained TCF1 expression. TCF1-silenced cells were T helper 1-like effectors and concentrated in the lungs. Cells from earliest divisions were memory-like and concentrated in nondraining LN. TCF1-expressing cells from later divisions in the DLN could self-renew, clonally yielding a TCF1-silenced daughter cell as well as a sibling cell maintaining TCF1 expression. Some TCF1-expressing cells in DLNs acquired an alternative, follicular helper-like fate. Modeled differentiation experiments in vitro suggested that unequal PI3K/mechanistic target of rapamycin signaling drives intraclonal cell fate heterogeneity. Asymmetric division enables self-renewal to be coupled to production of differentiated CD4+ effector T cells during clonal selection.
The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies
Authors: Ana Alicia López-Iglesias, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Daniel Primo, Mercedes Garayoa, Ana Belén Hernández, Teresa Paíno, Maria-Victoria Mateos, Yi Chen, Enrique M. Ocio, Thomas Mehrling
Journal: Blood (2014)
FDG-PET as a predicitve marker for primary resistance to imatinib (IM) in patients with gastrointestinal stromal tumors (GIST).
Authors: S. Oosting, M. W. Den Hollander, B. Rikhof, D. B. Rouw, J. R. De Jong, P. L. Jager, A. H. Brouwers, W. T. Van Der Graaf, E. De Vries, J. A. Gietema, A. K. L. Reyners
Journal: Journal of Clinical Oncology (2011)

10051 Background: A small number of patients (pts) with advanced GIST show primary resistance to IM, defined as progressive disease (PD) at first CT evaluation. Early recognition of resistance could prohibit side effects and save costs of ineffective treatment. IM can induce a rapid decrease in 18F-fluorodeoxyglucose (FDG) uptake in GIST. Aim of this study is to investigate if early change in tumor FDG uptake predicts primary IM resistance. Methods: Consecutive pts with metastatic or locally advanced GIST had FDG-PET scans before and 1 week after start of IM. Maximum Standardized Uptake Value (SUVmax) was determined and mean SUVmax for a maximum of 5 lesions per pt was calculated. Relationship between PET response (according to EORTC guidelines) and CT response (according to RECIST and Choi) after 2 months of treatment, was investigated. Results: 22 male and 14 female pts were included, mean age 62 years (range 23-81). 29 pts were treated in a palliative and 7 in a neo-adjuvant setting. 6 pts were not evaluable for PET response: 4 pts had no FDG-avid lesions, 2 pts had discordant PET scan protocols. 81 tumor lesions in 30 pts were quantified. Mean SUVmax on the first scan was 7.4 (SD 3.8, range 2.2-18.4) and on the second scan 3.0 (SD 2.1, range 0.1-11.8) (P<0.001). 26 pts had a metabolic response, 4 pts had metabolically stable disease. After 8 weeks of treatment 29 and 23 pts were evaluable according to RECIST and Choi criteria respectively (see table). PET response had a high positive predictive value (PPV) for clinical benefit (complete response (CR) or partial response (PR) or stable disease (SD)) according to RECIST: 92% (95% CI 74-99%) and Choi criteria: 95% (95% CI 76-100%). However, the false negative rate was 11% (95% CI 2-30%) resp. 9% (95% CI 1-30%) and pts with PD had a PET response. Conclusions: Although early FDG-PET response has a high PPV for clinical benefit from IM in pts with GIST, FDG-PET scans can not be used to predict primary resistance. CT RECIST (n=29) CT Choi (n=23) PET CR (n=1) +PR (n=9) +SD (n=17) PD (n=2) CR (n=1) +PR (n=16) +SD (n=5) PD (n=1) Response 24 2 20 1 No response 3 0 2 0
Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis
Authors: Mukta Arora, John P. Klein, Joseph H. Antin, Brian J. Bolwell, Michael Boyiadzis, Jean-Yves Cahn, Mitchell S. Cairo, Corey S. Cutler, Mary E.D. Flowers, Robert P. Gale, Anna Hassebroek, Roger H. Herzig, Mary M. Horowitz, Luis Isola, David A. Jacobsohn, Thomas R. Klumpp, Stephanie J. Lee, Effie W. Petersdorf, Stella Santarone, Harry C. Schouten, Stephen Spellman, Alvaro Urbano, Daniel J. Weisdorf, John R. Wingard, Steven Z. Pavletic
Journal: Blood (2010)
Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs)
Authors: Fengdong Cheng, Zi Wang, Hongwei Wang, Maritza Lienlaf, Karrune V. Woan, Patricio Perez-Villarroel, Jennifer Rock-Klotz, Eva Sahakian, Tessa Knox, David M Woods, John Powers, Rongxiang Han, Oscar Merino, Susan Deng, Danay Marante, Wayne W. Hancock, Alan Kozikowski, Joel Bergman, Javier Pinilla, Edward Seto, Eduardo M. Sotomayor, Alejandro Villagra
Journal: Blood (2012)
Pilot study on the correlation of multiphoton microscopy of human testicular tumors with histology.
Authors: Bobby B. Najari, Ranjith Ramasamy, Joshua Sterling, Amit Aggarwal, Seema Sheth, Manu Jain, Brian D. Robinson, Maria M. Shevchuk, Shahrokh F. Shariat, Sushmita Mukherjee, Douglas Scherr
Journal: Journal of Clinical Oncology (2012)

338 Background: Partial orchiectomy is becoming more accepted for indications such as a solitary testis, and small nonpalpable testicular masses found incidentally on scrotal ultrasonography. Unfortunately, intraoperative frozen-section pathological analysis is often unable to accurately predict the presence of malignancy. Multiphoton microscopy (MPM) enables in vivo imaging of tissue without the use of labeling techniques and could potentially diagnose testicular tumor pathology. We performed a non-randomized, non-controlled study to evaluate the feasibility of MPM to image testicular biopsies. Methods: Two men with testicular masses underwent radical orchiectomy for primary testicular tumor from June to August 2011. A total of six specimens from testicular tumor and uninvolved testes were imaged with MPM. In order to assess the diagnostic accuracy of MPM, we performed a blinded assessment by three uropathologists. The diagnosis rendered based on these images was then correlated with the findings seen on hematoxylin and eosin (H&amp;E) staining. Results: Our diagnosis based on MPM correlated with H&amp;E in five of six (83%) specimens. Images of seminoma acquired with the MPM are easily distinguished from those of teratoma and normal testicular parenchyma. Images of seminoma show abnormal architectural and cellular changes compared to cystic structures often seen with teratoma. Conclusions: Multiphoton microscopy can be used to reliably differentiate between teratoma, seminoma and normal testis tissue in our pilot group. MPM imaging could be potentially applied in intra-operative diagnosis of testicular tumors especially in testis-sparing surgery. Additional imaging of non-seminomatous germ cell tumors and non-germ cell tumors need to performed to verify the ultimate role of this technology.
Phase II Clinical Trial of Flavopiridol (FL) Followed by ara-c and Mitoxantrone (AM) for Adults with Relapsed and Refractory Acute Leukemias.
Authors: Judith E. Karp, B. Douglas Smith, Jacqueline Greer, Janet Briel, Mark J. Levis, Michael A. McDevitt, Steven D. Gore, A. Dimitrios Colevas
Journal: Blood (2005)
Abstract 2432: A technology platform for personalized medicine in melanoma
Authors: Maria R. Girotti, Dominic Rothwell, Amaya Viros, Amit Kumar Mandal, Kok Haw J. Lim, Gabriela Gremel, Simon Furney, Malin Pedersen, Jane Rogan, Jacqueline Swan, Alberto Fusi, Ged Brady, Paul Lorigan, Caroline Dive, Richard Marais
Journal: Cancer Research (2015)

Abstract We developed patient derived xenografts (PDX), performed whole exome sequencing (WES) and analyzed circulating tumor DNA (ctDNA) to complement clinical management of four melanoma patients. Synchronous treatment of patients and mice showed that PDX responses mirrored those of the patients’ tumor to BRAF inhibitors. PDXs were used to test second-line treatments in relapsed patients and to validate WES-based therapies in tumors that did not have a BRAF mutation. Longitudinal analysis of ctDNA was predictive of responses to targeted and immunotherapies, and to determine mechanisms of resistance. Thus, we describe a powerful combination of techniques for personalized medicine in melanoma and discuss the challenges and limitations of implementing these novel technologies in patient management. Citation Format: Maria R. Girotti, Dominic Rothwell, Amaya Viros, Amit Kumar Mandal, Kok Haw J. Lim, Gabriela Gremel, Simon Furney, Malin Pedersen, Jane Rogan, Jacqueline Swan, Alberto Fusi, Ged Brady, Paul Lorigan, Caroline Dive, Richard Marais. A technology platform for personalized medicine in melanoma. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2432. doi:10.1158/1538-7445.AM2015-2432
Stop Predatory Publishers Now
Authors: David Moher, Ester Moher
Journal: Annals of Internal Medicine (2016)

Letters6 December 2016Stop Predatory Publishers NowDavid Moher, PhD and Ester Moher, PhDDavid Moher, PhDFrom Ottawa Hospital Research Institute and Privacy Analytics, Ottawa, Ontario, Canada.Search for more papers by this author and Ester Moher, PhDFrom Ottawa Hospital Research Institute and Privacy Analytics, Ottawa, Ontario, Canada.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L16-0415 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Winker for pointing out all of the collaborative work that the World Association of Medical Editors is doing with other players in the area of predatory journals, particularly around issues related to identifying such journals. Winker and this organization also make an important point about the gray zone that new and emerging legitimate journals can fall into and thus erroneously become blacklisted. We make this very point in our essay.Whatever the appropriate definition attributed to predatory journals—which, like many other definitions, will be imperfect (1, 2)—we believe that our central point remains. A large ...References1. Moher D, Cole CW, Hill GB. Epidemiology of abdominal aortic aneurysm: the effect of differing definitions. Eur J Vasc Surg. 1992;6:647-50. [PMID: 1451823] CrossrefMedlineGoogle Scholar2. Goodman SN, Fanelli D, Ioannidis JP. What does research reproducibility mean? Sci Transl Med. 2016;8:341ps12. [PMID: 27252173] doi:10.1126/scitranslmed.aaf5027 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Ottawa Hospital Research Institute and Privacy Analytics, Ottawa, Ontario, Canada.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-3015. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoStop Predatory Publishers Now: Act Collaboratively David Moher and Ester Moher Stop Predatory Publishers Now Margaret A. Winker and Metrics Cited byInvitations received from potential predatory publishers and fraudulent conferences: a 12-month early-career researcher experienceOpen Access: Is There a Predator at the Door?Open Access: Is There a Predator at the Door? 6 December 2016Volume 165, Issue 11Page: 826-827KeywordsConflicts of interestDisclosureFallsMedical educationPeer reviewPerceptionRandomized trials ePublished: 6 December 2016 Issue Published: 6 December 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Milk Thistle Is Associated with Reductions in Liver Function Tests (LFTs) in Children Undergoing Therapy for Acute Lymphoblastic Leukemia (ALL).
Authors: Elena J. Ladas, Bin Cheng, Deborah Hughes, David J. Kroll, T.N. Graf, N.H. Oberlies, Susan Rheingold, Nancy Sacks, Kara M. Kelly
Journal: Blood (2006)
Donor-Specific Tolerance Is Induced after Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation and May Persist after Graft Rejection.
Authors: Murad Y. Yunusov, Kraig Abrams, Christian S. Kuhr, Rainer Storb, Billanna Hwang, George E. Sale, Barry Storer, George E. Georges, Richard A. Nash
Journal: Blood (2005)
Third Party Donor Derived EBV Specific T Cells for the Treatment of Refractory EBV-Related Malignancies in Immunodeficient Recipients
Authors: Susan E. Prockop, Ekaterina Doubrovina, Juliet N Barker, Karim Baroudy, Farid Boulad, Ramzi Khalaf, Nancy A. Kernan, Rachel Kobos, Esperanza B. Papadopoulos, Andromachi Scaradavou, Trudy N Small, Gloria Wasilewski, Richard J. O'Reilly
Journal: Blood (2012)
Mold and dampness exposure and allergic outcomes from birth to adolescence: data from the BAMSE cohort
Authors: J. D. Thacher, O. Gruzieva, G. Pershagen, E. Melén, J. C. Lorentzen, I. Kull, A. Bergström
Journal: Allergy (2016)

Abstract Background Exposure to moldy or damp indoor environments is associated with allergic disease in young children, but it is unclear whether the effects persist to adolescence. Our objective was to assess whether exposure to mold or dampness during infancy increases the risk of asthma, rhinitis, or IgE sensitization in children followed from birth to 16 years of age. Methods We collected questionnaire derived reports of mold or dampness indicators and allergic outcomes from 3798 children in a Swedish birth cohort ( BAMSE ). Sensitization was assessed from blood samples in 3293 children. Longitudinal associations between prevalent asthma, rhinitis, and IgE sensitization and mold or dampness indicators were assessed using generalized estimating equations. Results Exposure to any mold or dampness indicator was associated with asthma up to 16 years of age ( OR 1.31; 95% CI 1.08–1.59), while exposure to mold odor ( OR 1.29; 95% CI 1.03–1.62) and visible mold ( OR 1.28; 95% CI 1.04–1.58) were associated with rhinitis. Increased risks were observed for nonallergic asthma ( OR 1.80; 95% CI 1.27–2.55) and rhinitis ( OR 1.41; 95% CI 1.03–1.93). No association was observed between mold or dampness indicators and IgE sensitization. Exposure to any mold or dampness indicator was associated with persistent asthma ( OR 1.73; 95% CI 1.20–2.50), but not with early‐transient or late‐onset asthma. Conclusion Exposure to mold or dampness during infancy increased the risk of asthma and rhinitis up to 16 years of age, particularly for nonallergic disease. Early exposure to mold or dampness appeared particularly associated with persistent asthma through adolescence.
Betaherpesvirus Reactivation and Toll-Like Receptor Expression After Allogeneic Stem Cell Transplantation
Authors: Cristina Skert, Manuela Fogli, Simone Perucca, Simona Fiorentini, Emirena Garrafa, Carla Filì, Chiara Colombi, Annalisa Peli, Cesare Bergonzi, Michele Malagola, Elisa Alghisi, Alessandro Turra, Arnaldo Caruso, Domenico Russo
Journal: Blood (2011)
Orientation-Dependent Regulation of RUNX1 and GATA-1 Transcriptional Function by the p300/CBP Coactivators.
Authors: Ivailo S. Mihaylov, Kamaleldin E. Elagib, Lorrie L. Delehanty, Sara L. Gonias, Jill F. Caronia, Adam N. Goldfarb
Journal: Blood (2006)
Transient Mixed Chimerism after Stem Cell Transplantation Can Induce Durable Molecular Complete Remissions in Chronic Myelogenous Leukemia.
Authors: Guillermo J. Ruiz-Arguelles, David Gomez-Almaguer, Guillermo J. Ruiz-Delgado, Luz del Carmen Tarin-Arzaga
Journal: Blood (2006)